Overactive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial Sarcoma
Open Access
Abstract
Pazopanib is approved for treatment of advanced soft tissue sarcomas, but primary and secondary drug resistance limits its clinical utility. We investigated the molecular mechanisms mediating pazopanib resistance in human synovial sarcoma (SS) models. We found reduced cell sensitivity to pazopanib associated with inefficient inhibition of the two critical signaling nodes, AKT and ERKs, despite strong inhibition of the main drug target, PDGFRα. In the CME-1 cell line, overactivation of IGF1 and Insulin receptors (IGF1R/InsR) sustained AKT activation and pazopanib resistance, which was overcome by a combination treatment with the double IGF1R/InsR inhibitor BMS754807. In the highly pazopanib resistant MoJo cell line, NRASQ61R mutation sustained constitutive ERK activation. Transfection of the NRAS mutant in the pazopanib sensitive SYO-1 cell line increased the drug IC50. MoJo cells treatment with pazopanib in combination with the MEK inhibitor trametinib restored ERK inhibition, synergistically inhibited cell growth, and induced apoptosis. The combination significantly enhanced the antitumor efficacy against MoJo orthotopic xenograft abrogating growth in 38% of mice. These findings identified two different mechanisms of intrinsic pazopanib resistance in SS cells, supporting molecular/immunohistochemical profiling of tumor specimens as a valuable approach to selecting patients who may benefit from rational drug combinations.Keywords
Funding Information
- Associazione Bianca Garavaglia (A/18/01B)
This publication has 70 references indexed in Scilit:
- Loss of SS18-SSX1 Inhibits Viability and Induces Apoptosis in Synovial SarcomaClinical Orthopaedics and Related Research, 2014
- Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial SarcomaCell, 2013
- PDGF Receptor Alpha Is an Alternative Mediator of Rapamycin-Induced Akt Activation: Implications for Combination Targeted Therapy of Synovial SarcomaCancer Research, 2012
- Dual‐specificity MAP kinase phosphatases (MKPs)The FEBS Journal, 2012
- Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212Molecular Cancer Therapeutics, 2012
- Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesisGenes & Development, 2011
- Phosphatidylinositol‐3′‐kinase/AKT signaling is essential in synovial sarcomaInternational Journal of Cancer, 2010
- Synovial Sarcoma Is a Stem Cell MalignancyStem Cells, 2010
- Guidelines for the welfare and use of animals in cancer researchBritish Journal of Cancer, 2010
- The Synovial Sarcoma–Associated SS18-SSX2 Fusion Protein Induces Epigenetic Gene (De)RegulationCancer Research, 2006